The Non-Financial Ledger: What Numbers Can’t Capture

Think about the last time you stood in a pet store aisle reading the back of a dog food bag. You squinted at the ingredients. You looked for anything that sounded harmful. You wanted to do right by the animal that trusts you completely and expects nothing back except to be fed and loved. That is the moment Schell & Kampeter exploited.

DCM does not announce itself. It moves quietly. A dog’s heart slowly loses its ability to pump blood. The left ventricle stretches and weakens over months, sometimes years, and the dog shows nothing on the outside. By the time a dog is gasping, struggling to breathe, collapsing during a walk, or simply dead in the morning from a sudden fatal arrhythmia, the disease has been building for a long time. The complaint describes this hidden phase as the “occult” period, and it can last years. Dogs don’t complain. They just deteriorate, invisibly, while their owners keep filling their bowls with what they were told was the healthy, natural choice.

The complaint documents that some dogs died. Others were diagnosed and their owners had to scramble for cardiologists, echocardiograms, and cardiac medications that are expensive enough to wreck a household budget. Some dogs recovered after switching food, which means the suffering was preventable. Some did not recover. The owners of those dogs spent money on necropsies to find out what killed their pet, because nothing on the packaging gave them any warning that the food they trusted was the problem.

The cruelest detail in this entire case is simple: Schell & Kampeter’s own Director of Veterinary Affairs kept her personal dog off this product. She knew. The people who sold the food to you had already decided they would not feed it to their own animals.

Legal Receipts: Straight from the Record

The following are verbatim statements from the complaint filed in Case 3:26-cv-03723-RFL. Each one is drawn directly from the court document without modification.

“Defendant conducted no feeding study to assess the safety of its novel Taste of the Wild grain-free dog food prior to launching it in 2007. To this day Defendant has not publicly disclosed any feeding study substantiating any of its health and safety claims.”

“In May 2019, in response to a consumer whose dog died from diet-associated DCM after eating a Taste of the Wild grain-free dog food diet for the majority of its life, Defendant stated that ‘[T]he FDA has not listed any specific pet diets, food ingredients or manufacturers as a cause of DCM … I don’t know where you found it saying we use 6 week feeding trials. Like a lot on the internet, this is blatantly untrue. When we do feeding trials it is the standard 6 months long, like the other pet food manufacturers use.'”

“Internally, Defendant’s Director of Veterinary Affairs recommended to an employee concerned about the association of DCM and Taste of the Wild grain-free dog food that she switch her dogs to a grain-inclusive diet. She also recommended to a consumer that she not feed her dog Taste of the Wild grain-free dog food because the dog was a breed predisposed to DCM, and stated that she does not feed her own dog Taste of the Wild grain-free dog food because her dog was a breed predisposed to DCM.”

“Defendant has represented that it does not feel compelled to conduct these studies because it believes the onus is on those claiming Taste of the Wild grain-free dog food is unsafe to prove their allegations, rather than on Defendant to ensure the safety of its own products.”

“Defendant has actively suppressed public knowledge of the FDA’s investigation and veterinary recommendations that pet owners avoid feeding dogs grain-free dog foods by attempting to block or remove public comments on various product review websites that refer to the FDA’s reports or that discuss or suggest a link between Taste of the Wild grain-free dog food and DCM.”

Public Deception: What They Said vs. What They Knew

Schell & Kampeter built and maintained a public-facing narrative about Taste of the Wild that directly contradicted what the company knew internally about its product’s risks.

• Claim: The product packaging and website represented Taste of the Wild as “a modern diet, inspired by nature” providing dogs “all the nutrition they need to thrive,” that it is “complete and balanced,” and that “every formula is designed to keep your pet healthy.” Reality: The company had been receiving consumer reports of cardiac deaths linked to the product since at least 2018 and was aware of accumulating scientific studies connecting grain-free, high-legume diets to DCM and related cardiac damage.
• Claim: The packaging stated legume ingredients “provide nutrients that help support your dog’s overall well-being” and described them as “a superfood packed with protein and essential nutrients.” Reality: Scientific studies showed dogs eating grain-free, high-legume foods exhibited elevated cardiac biomarkers including NT-proBNP and cardiac troponin-I, markers of heart muscle stretching and injury. Legumes were a cheaper replacement for grains, not a health-optimized ingredient choice.
• Claim: The website stated “safety is our top priority” and that the company “adheres to stringent and scientifically advanced food safety protocols” and conducts “feeding trials to ensure the safest and most nutritious food possible.” Reality: The company conducted no feeding studies on cardiac outcomes, employed no board-certified veterinary nutritionist during formula development, and explicitly told investigators it did not feel obligated to conduct safety studies on its own product.
• Claim: In response to consumer inquiries, company agents asserted the FDA’s DCM investigation had concluded and that the FDA determined Taste of the Wild was not associated with DCM. Reality: The FDA did not clear the product. In December 2022, the FDA announced it would not release further investigation updates but explicitly did not exonerate any brand. The investigation had named Taste of the Wild as the third most commonly reported brand in FDA DCM cases.
• Claim: The company stated it “promises to be transparent and clear about what goes into our products and your dog’s bowl.” Reality: Searching “DCM,” “dilated cardiomyopathy,” “cardiac risk,” or “heart damage” on Taste of the Wild’s website returns zero results. The company wrote letters to veterinarians pressing them to stop recommending against the product.

Regulatory Gray Zones: How the Rules Let This Happen

The pet food industry operates in a space where no federal agency reviews or pre-approves commercial dog food as “safe” before it hits shelves, a gap Schell & Kampeter exploited across nearly two decades of sales.

• The FDA’s Center for Veterinary Medicine does not pre-screen commercial pet food formulas for safety the way it reviews animal drugs. The complaint directly quotes then-FDA CVM Director Dr. Steven Solomon: “CVM does not review or declare any particular type of pet food as ‘safe’ the way we do with animal drugs.” This means a manufacturer can launch an entirely novel formula with zero independent safety verification and no regulatory sign-off.
• When grain-free dog food entered the market in 2007, it was genuinely novel territory. The complaint notes grain-free products occupied less than 1% of the dog food market at that time. No existing regulation required pre-market cardiac safety testing for this new category. The company had industry knowledge that lamb-and-rice diets from the 1980s and 1990s had later been linked to DCM, establishing a clear precedent that novel formulas carry cardiac risks, but no rule compelled them to act on that knowledge.
• The FDA’s response to emerging DCM reports, beginning in July 2018, was framed explicitly as “a matter of science” rather than a regulatory enforcement action. Dr. Solomon stated the agency did “not view this as a regulatory issue.” This framing gave manufacturers no binding obligation to change labels, issue warnings, conduct studies, or cooperate with the investigation. It was entirely voluntary, and Schell & Kampeter declined to volunteer.
• The complaint notes that knowledge of DCM risk “was, and remains, largely confined to veterinary academia and industry participants.” Pet food manufacturers are embedded in that academic and professional ecosystem. The information existed; the obligation to share it with consumers did not.

Profit-Maximization at All Costs

The financial architecture of Taste of the Wild’s grain-free line was built on substituting cheaper ingredients for more expensive ones, charging a premium price justified by health claims those ingredients actively contradict.

• The complaint states directly: legume ingredients are “less expensive than animal protein ingredients, which lowers Defendant’s cost of manufacturing Taste of the Wild grain-free food in comparison to dog food that contains grain.” The company replaced grains with legumes to cut manufacturing costs, then marketed legumes as a “superfood” to justify a higher retail price.
• Grain-free dog food grew from under 1% of the market in 2007 to nearly 25% of all dog food sold over the following decade. Schell & Kampeter claims to be the number one seller of grain-free dog food in the United States. Revenue from this category is described in the complaint as likely amounting to tens of millions of dollars.
• By 2015, Schell & Kampeter had expanded to seventeen grain-free, high-legume recipes. Each formula revision increased the concentration of legume ingredients. The complaint describes a deliberate trend: “Defendant capitalized on the grain-free trend and continued to both add grain-free recipes to its catalog of dog foods and increase the quantities of legume ingredients in its recipes.” Higher legume content means lower ingredient cost per unit sold.
• Plaintiff Vilekar paid approximately $47.00 every one and a half to two months from July 2022 to November 2024, paying a premium for a product that the company’s own internal veterinary expert had identified as a health risk warranting avoidance.
• The complaint alleges the misrepresentations “were designed to drive greater product sales and allow Defendant to charge a premium price because consumers who buy the dog food are willing to pay more for products represented as safe, healthy, and resembling a natural diet than for products sold without such representations.”

The Chronology: A Timeline of Knowledge and Silence

Time as a Corporate Weapon: 17 Years of Strategic Silence

Schell & Kampeter’s most effective tool was not its marketing budget; it was the clock. Every year the company avoided a recall, a label change, or a safety disclosure was another year of grain-free premium revenue.

• The company launched Taste of the Wild in 2007 knowing, from the history of lamb-and-rice diet studies in the 1990s, that novel formulas carried cardiac risk. It conducted no pre-launch testing. That decision bought years of uncontested sales before the scientific community caught up with the specific grain-free, high-legume formulation.
• By approximately 2009, veterinary cardiologists were already observing DCM in non-predisposed dogs on grain-free diets. This internal signal within the veterinary community took nearly a decade to generate enough documented cases and published studies to prompt federal attention. For those nine years, the product’s risks stayed inside academic journals and veterinary conferences while consumers kept buying bags at a premium.
• When the FDA opened its investigation in July 2018, it asked pet food manufacturers including Schell & Kampeter to cooperate by providing diet formulations. The company refused. That refusal is documented in the complaint. Refusal to cooperate is a delay tactic: without the manufacturer’s proprietary formulation data, investigators must reconstruct the analysis from outside, which takes longer.
• The complaint also documents that Schell & Kampeter “engaged in an expansive lobbying campaign” to slow and ultimately terminate the FDA’s public reporting on the DCM investigation. In December 2022, the FDA announced it would not issue further updates. The complaint states the company’s “pressure tactics were largely successful.” The investigation did not produce a regulatory finding, a recall, or a mandatory label change. The product continued to be sold exactly as before.
• The ongoing litigation in Missouri referenced in the complaint suggests this case was not the first legal challenge the company has faced on this issue. Continuing to sell through litigation rather than reformulating or warning is itself a delay tactic: the cost-benefit calculation favors continued sales over the risk of any individual lawsuit reaching judgment.